Form 4: Alnylam Pharmaceuticals Executive Indrani Franchini Reports Stock Transactions
SEC Form 4 Filing
Indrani Franchini, EVP, CLO & Secretary of Alnylam Pharmaceuticals, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.
Summary
- On February 27, 2024, Indrani Franchini, EVP, CLO & Secretary of Alnylam Pharmaceuticals, had restricted stock units vest, resulting in the acquisition of 878 shares.
- To cover statutory tax withholding obligations, 878 shares were sold at a price of $0.0.
- On February 28, 2024, Franchini sold a total of 329 shares in multiple transactions at weighted average prices ranging from $154.54 to $158.09.
- Following these transactions, Franchini directly owns 4,133 shares of Alnylam Pharmaceuticals common stock.
- Franchini also holds 1,754 restricted stock units.
Sentiment
Score: 5
Explanation: This Form 4 filing reflects routine transactions related to executive compensation and tax obligations, indicating a neutral sentiment.
Industry Context
Form 4 filings are a routine part of the US market and provide transparency into the transactions of company insiders, allowing investors to track executive sentiment and potential alignment with shareholder interests.
Key Dates
| Date | Description |
|---|---|
| 02/27/2023 | Reporting person was granted 2,632 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. |
| 02/27/2024 | Restricted stock units vested and were released. |
| 02/28/2024 | Shares sold in multiple transactions. |
| 02/29/2024 | Date of Form 4 signature. |
| 02/27/2026 | Expiration date of restricted stock units. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.